NCT03533959View on ClinicalTrials.gov

To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy

RecruitingOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2025

Conditions
Coronary Artery Disease Progression
Interventions
DRUG

Alirocumab

the administration of Alirocumab at least 75mg every 2 weeks

Trial Locations (1)

650-0017

RECRUITING

Kobe University Graduate School of Medicine, Department of Cardiology, Kobe

All Listed Sponsors
lead

Kobe University

INDUSTRY